Whole-Genome Sequencing and Genetic Diversity of Human Respiratory Syncytial Virus in Patients with Influenza-like Illness in Sicily (Italy) from 2017 to 2023.
Humans
Respiratory Syncytial Virus, Human
/ genetics
Genetic Variation
Respiratory Syncytial Virus Infections
/ virology
Sicily
/ epidemiology
Phylogeny
Whole Genome Sequencing
Child, Preschool
Infant
Female
Male
Child
Genotype
Adult
Adolescent
Genome, Viral
Middle Aged
Young Adult
Aged
Influenza, Human
/ virology
Amino Acid Substitution
Infant, Newborn
Italy
Sicily
amino acid change
community
mAb
molecular surveillance
respiratory syncytial virus
vaccine
whole-genome sequencing
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
26 May 2024
26 May 2024
Historique:
received:
02
05
2024
revised:
21
05
2024
accepted:
24
05
2024
medline:
27
6
2024
pubmed:
27
6
2024
entrez:
27
6
2024
Statut:
epublish
Résumé
Monitoring the genetic variability of human respiratory syncytial virus (hRSV) is of paramount importance, especially for the potential implication of key antigenic mutations on the emergence of immune escape variants. Thus, to describe the genetic diversity and evolutionary dynamics of hRSV circulating in Sicily (Italy), a total of 153 hRSV whole-genome sequences collected from 770 hRSV-positive subjects between 2017 and 2023, before the introduction of expanded immunization programs into the population, were investigated. The phylogenetic analyses indicated that the genotypes GA.2.3.5 (ON1) for hRSV-A and GB.5.0.5a (BA9) for hRSV-B co-circulated in our region. Amino acid (AA) substitutions in the surface and internal proteins were evaluated, including the F protein antigenic sites, as the major targets of immunoprophylactic monoclonal antibodies and vaccines. Overall, the proportion of AA changes ranged between 1.5% and 22.6% among hRSV-A, whereas hRSV-B varied in the range 0.8-16.9%; the latter was more polymorphic than hRSV-A within the key antigenic sites. No AA substitutions were found at site III of both subgroups. Although several non-synonymous mutations were found, none of the polymorphisms known to potentially affect the efficacy of current preventive measures were documented. These findings provide new insights into the global hRSV molecular epidemiology and highlight the importance of defining a baseline genomic picture to monitor for future changes that might be induced by the selective pressures of immunological preventive measures, which will soon become widely available.
Identifiants
pubmed: 38932144
pii: v16060851
doi: 10.3390/v16060851
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Merck Sharp & Dohme Corp
ID : MISP IIS58826